CNBC June 29, 2023
Key Points
– Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug as a treatment for idiopathic pulmonary fibrosis, a chronic lung disease.
– “It is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients,” Alex Zhavoronkov, founder and CEO of Insilico Medicine, told CNBC.
– The discovery process for the new drug began in 2020.
The first drug fully generated by artificial intelligence entered clinical trials with human patients this week.
Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for idiopathic pulmonary fibrosis, a chronic disease that causes scarring...
Today's Sponsors
Today's Sponsor